Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops medicines for human disease. Founded in 1995 and headquartered in The Woodlands, Texas, the company uses its drug-discovery platform and expertise in biology to identify potential treatments for conditions with significant unmet medical needs.
Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral medicine used to treat carcinoid syndrome diarrhea in adults whose symptoms are not adequately controlled by somatostatin analog therapy. The company also developed INPEFA (sotagliflozin), a sodium-glucose cotransporter inhibitor approved in the United States for certain adults with heart failure and for patients with type 2 diabetes, chronic kidney disease, and cardiovascular risk factors.
In addition to its commercial products, Lexicon maintains a pipeline of investigational medicines in areas including cardiometabolic disease, neuropathic pain, and other serious disorders. The company has historically worked with larger pharmaceutical partners to support the development, regulatory approval, and commercialization of its therapies, enabling its products to reach patients in the United States and selected international markets.
Lexicon is led by Lonnel Coats, who serves as president and chief executive officer. Its research and development activities are primarily based in the United States, while the geographic availability of its products depends on regulatory approvals and commercial arrangements in individual markets.
AI Generated. May Contain Errors.
